Literature DB >> 21048355

Synthesis of acinetobactin.

Yasuo Takeuchi1, Satoru Ozaki, Masahiro Satoh, Ken-ichiro Mimura, Sei-ichi Hara, Hitoshi Abe, Hiromi Nishioka, Takashi Harayama.   

Abstract

A structure involving the absolute configuration of acinetobactin (1b) was clarified. It was reconfirmed that preacinetobactin (1a) produced 1b by a rearrangement reaction.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21048355     DOI： 10.1248/cpb.58.1552

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


  5 in total

1.  Non-nucleoside inhibitors of BasE, an adenylating enzyme in the siderophore biosynthetic pathway of the opportunistic pathogen Acinetobacter baumannii.

Authors:  João Neres; Curtis A Engelhart; Eric J Drake; Daniel J Wilson; Peng Fu; Helena I Boshoff; Clifton E Barry; Andrew M Gulick; Courtney C Aldrich
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

2.  Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.

Authors:  Timothy A Wencewicz; Marvin J Miller
Journal:  J Med Chem       Date:  2013-05-08       Impact factor: 7.446

3.  Distinctive Roles of Two Acinetobactin Isomers in Challenging Host Nutritional Immunity.

Authors:  Mingi Kim; Do Young Kim; Woon Young Song; So Eun Park; Simone A Harrison; Walter J Chazin; Man Hwan Oh; Hak Joong Kim
Journal:  mBio       Date:  2021-09-14       Impact factor: 7.867

4.  Synthesis and Characterization of Preacinetobactin and 5-Phenyl Preacinetobactin.

Authors:  Jean M Bray; Scott Pierce; Alfredo M Angeles-Boza; Mark W Peczuh
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

Review 5.  The diversity and utility of arylthiazoline and aryloxazoline siderophores: challenges of total synthesis.

Authors:  Karolina Kamińska; Andrzej Mular; Evgenia Olshvang; Nils Metzler Nolte; Henryk Kozłowski; Elżbieta Wojaczyńska; Elżbieta Gumienna-Kontecka
Journal:  RSC Adv       Date:  2022-09-07       Impact factor: 4.036
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.